Outpatients with chronic kidney disease stage 3-5 in department of medicine, Kidney Center of Tokyo Women'
Conditions
Interventions
Lanthanum carbonate is administered for 12 weeks. Dose of lanthanum carbonate is 750-2250 mg/day. Lanthanum carbonate is administered 3 times/day.
Calcium carbonate is administered for 12 weeks. D
Sponsors
Department of Medicine, Kidney Center, Tokyo Women's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Over 20 years old when informed concent 2)Chronic Kidney Disease stage 3-5(GFR<60 ml/min/1.73m2) 3)Patients over 3.0 mg/dL of serum phosphate levels and without treatments with phosphate binders 4)Patients who provided written concent to participate in this study after a sufficient explanation.
Exclusion criteria
Exclusion criteria: 1)Patients who have a contraindication that is shown in the product documents of lanthanum carbonate or calcium carbonate. 2)Patients with malignant diseases or the possibility of maignant diseases of entry. 3)Patients with a past history of renal transplantation. 4)Pregnant women or women with possibility of pregnancy. 5)Patients who made a judgmental decision as an inadequate patient by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of serum Fetuin-A levels between two groups treated with lanthanum carbonate and calcium carbonate | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum levels of phosphate, calcium, intact PTH, high sensitive CRP, FGF23, Klotho, calcium protein particle, matrix gla protein, osteoprotegerin, osteopontin, Apo B48, MDA-LDL, and pentraxin 3. | — |
Countries
Japan
Contacts
Public ContactYukari Asamiya
Tokyo Women's Medical University Department of Medicine, Kidney Center
Outcome results
None listed